Opposing effects of two CCK(B) agonists on the retrieval phase of a two-trial memory task after systemic injection in the rat

Neuropharmacology

Volumn 38, Issue 4, 1999, Pages 543-553

  Léna, Isabelle ^a   Simon, Hervé ^b   Roques, Bernard P ^a   Daugé, Valérie ^a  

^a Laboratoire de Pharmacochimie   (France)

^b INSERM   (France)

Author keywords

BC 197 and BC 264; CCK(B) agonists; CCK(B) receptors heterogeneity; Retrieval processes; Spatial recognition memory

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; AMPHETAMINE; BC 197; BC 264; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; INFORMATION RETRIEVAL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MEMORY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANIMALS; BENZODIAZEPINONES; CHOLECYSTOKININ; COGNITION; DEVAZEPIDE; DOPAMINE UPTAKE INHIBITORS; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; MEMORY; MUSCARINIC ANTAGONISTS; PEPTIDE FRAGMENTS; PHENYLUREA COMPOUNDS; RATS; RATS, WISTAR; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; SCOPOLAMINE; SPACE PERCEPTION;

EID: 0344334076     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(98)00223-8     Document Type: Article

References (51)

1. Akagi K., Nagao T., Urushidani T. Calcium oscillations in single cultured chinese hamster ovary cells stably transfected with a cloned human cholecystokinin (CCK)B receptor. Jpn. J. Pharmacol. 75:1997;33-42.
2. Bock M.G., Dipardo R.M., Evans B.E., Rittle K.E., Whitter W.L., Veber D.F., Anderson P.S., Freidinger R.M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L 365,260. J. Med. Chem. 32:1989;13-16.
3. Bushnell P.J., Levin E.D. Effects of dopaminergic drugs on working and reference memory in rats. Pharmacol. Biochem. Behav. 45:1993;765-776.
4. Caine E.D, Weingartner H., Ludlow C.L., Cudahy E.A., Wehry S. Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology. 74:1981;74-80.
5. Chang, R.S.L., Lotti, V.J., 1986. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. USA 83, 4923-4926.
6. Charpentier B., Durieux C., Pélaprat D., Dor A., Reibaud M., Blanchard J.-C., Roques B.P. Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides. 9:1988a;835-841.
7. Charpentier B., Pélaprat D., Durieux C., Dor A., Reibaud M., Blanchard J.-C., Roques B.P. Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc. Natl. Acad. Sci. USA. 85:1988b;1968-1972.
8. Charrier D., Dangoumau L., Puech A.J., Hamon M., Thiebot M.-H. Failure of CCK receptor ligands to modify anxiety-related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology. 121:1995;127-134.
9. Crawley J.N., Corwin R.L. Biological actions of cholecystokinin. Peptides. 15:1994;731-755.
10. Daugé V., Böhme G.A., Crawley J.N., Durieux C., Stutzmann J.M., Féger J., Blanchard J.C., Roques B.P., 1990. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264. Synapse, 6, 73-80.
11. Dellu F., Mayo W., Cherkaoui J., LeMoal M., Simon H. A two trial memory task with automated recording: study in young and aged rats. Brain Res. 588:1992;132-139.
12. Dellu F., Fauchey V., LeMoal M., Simon H. Extension of a new two-trial memory task in the rat: influence of environmental context on recognition processes. Neurobiol. Learn. Mem. 67:1997;112-120.
13. Derrien M., Daugé V., Blommaert B., Roques B.P. The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. Behav. Brain Res. 65:1994a;139-146.
14. Derrien M., McCort-Tranchepain I., Ducos B., Roques B.P., Durieux C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 49:1994b;133-141.
15. Detjen K., Tseng M.-J., Logsdon C.D. High- and low-affinity CCKA receptor states mediate specific growth inhibitory effects on CHO cells. Biochem. Biophys. Res. Commun. 213:1995;44-51.
16. Detjen K., Yule D., Tseng M.-J., Williams J.A., Logsdon C.D. CCK-B receptors produce similar signals but have opposite growth effects in CHO and Swiss 3T3 cells. Am. J. Physiol. 42:1997;C1449-C1457.
17. Dourish C.T., Hawley D., Iversen S. D. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. Eur. J. Pharmacol. 147:1988;469-472.
18. Dourish C.T., O'Neill M.F., Coughlan J., Kitchener S.J., Hawley D., Iversen S.D. The selective CCK-B receptor antagonist L-365-260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176:1990;35-44.
19. Durieux C., Coppey M., Zajac J.M., Roques B.P. Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. Biochem. Biophys. Res. Commun. 137:1986;1167-1173.
20. Durieux C., Derrien M., Maldonado R., Valverde O., Blommaert A., Fournié-Zaluski M.-C., Roques B.P. CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration. Ann. NY Acad. Sci. 713:1994;355-357.
21. Eckerman D., Gordon W.A., Edwards J.D., McPhail R.C., Gage M.I. Effects of scopolamine, pentobarbital, and amphetamine on radial arm maze performance in the rat. Pharmacol. Biochem. Behav. 12:1980;595-602.
22. Hadjiivanova C., Kehayov R., Petkov V.V., Amblard M., Martinez J. Behavioral effects of the cyclic cholecystokinin peptide analogue JMV-320. Peptides. 5:1995;815-819.
23. Harper E.A., Roberts S.P., Shankley N.P., Black J.W. Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br. J. Pharmacol. 118:1996;1717-1726.
24. Harro J., Oreland L. Cholecystokinin receptors and memory: a radial maze study. Pharmacol. Biochem. Behav. 44:1993;509-517.
25. Hill D.R., Campbell N.J., Shaw T.M., Woodruff G.N. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J. Neurosci. 7:1987;2967-2976.
26. Huang S.C., Fortune K.P., Wank S.A., Kopin A.S., Gardner J.D. Multiple affinity states of different cholecystokinin receptors. J. Biol. Chem. 269:1994;26121-26126.
27. Huston J.P., Hasenöhrl R.U., Boix F., Gerhardt P., Schwarting R.K.W. Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity. Psychopharmacology. 112:1993;147-162.
28. Itoh S., Lal H. Influences of cholecystokinin and analogues on memory processes. Drug Dev. Res. 21:1990;257-276.
29. Itoh S., Takashima A., Maeda Y. Memory impairments induced by peripherally administered cholecystokinin A-type receptor antagonists in rats. Drug Dev. Res. 26:1992;89-99.
30. Kesner R.P., Bierley R.A., Pebbles P. Short-term memory: the role of D-amphetamine. Pharmacol. Biochem. Behav. 15:1981;673-676.
31. 26-33): evidence for CCK-B receptor heterogeneity. J. Pharmacol. Exp. Ther. 255:1990;1278-1286.
32. Ladurelle N., Keller G., Blommaert A., Roques B.P., Daugé V. The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal infection in rats. Eur. J. Neurosci. 9:1997;1804-1814.
33. Leff P., Scaramellini C., Law C., McKechnie K. A three-state receptor model of agonist action. Trends Pharmacol. Sci. 18:1997;355-362.
34. Léna I., Roques B.P., Durieux C. Dual modulation of dopamine release from anterior nucleus accumbens through cholecystokinin-B receptors subsites. J. Neurochem. 68:1997;162-168.
35. Lemaire M., Piot O., Roques B.P., Böhme G.A., Blanchard J.C. Evidence for an endogenous cholecystokininergic balance in social memory. Neuroreport. 3:1992;929-932.
36. Lemaire M., Böhme G.A., Piot O., Roques B.P., Blanchard J.C. CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology. 115:1994;435-440.
37. Melville L.D., Smith G.P., Gibbs J. Devazepide antagonizes the inhibitory effect of cholecystokinin on intake in sham-feeding rats. Pharmacol. Biochem. Behav. 43:1992;975-977.
38. Mercer L.D., Beart P.M. Histochemistry in rat brain and spinal cord with an antibody directed at the cholecystokininA receptor. Neurosci. Lett. 225:1997;97-100.
39. Million, M.-E., Léna, I., Da Nascimento, S., Noble, F., Daugé, V., Garbay, C., Roques, B.P., 1997. Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCK-B receptor. Lett. Peptide Sci., 4, 407-410.
40. Noble F., Smadja C., Roques B.P. Role of endogenous cholecystokinin in the facilitation of μ-mediated antinociception by δ-opioid agonists. J. Pharmacol. Exp. Ther. 271:1994;1127-1134.
41. O'Neill M.F., Dourish C.T., Iversen S.D. Morphine-induced analgesia in the rat paw pressure test is blocked by CCK and enhanced by the CCK antagonist MK-329. Neuropharmacology. 28:1989;243-247.
42. Palmour, A.M., Durieux, C., Roques, B.P., Bertrand, P., Capet, M., Dubroeucq, M.-C., Howbert, J.J., Woodruff, G., Bradwejn, J., Ervin, F.R., 1993. Anxiogenic effects of CCK agonists in a non-human primate model: central or peripheral? (Abstract) CCK 93, May 19-22, Chatham, Cape Cod, USA, p. 52.
43. de St-Hilaire Z., Roques B.P., Nicolaïdis S. Effect of a highly selective central CCK-B receptor agonist: BC-264 on rat sleep. Pharmacol. Biochem. Behav. 38:1991;545-548.
44. Sara S.J., Deweer B. Memory retrieval enhanced by amphetamine after a long retention interval. Behav. Neural Biol. 36:1982;146-160.
45. Schulteis G., Martinez J.L. Jr., Hruby V.J. (1988) Stimulation and antagonism of opioid δ receptors produce opposite effect on active avoidance conditioning in mice. Behav. Neurosci., 102, 678-686.
46. Singh L., Oles R.J., Field M.J., Atwal P., Woodruff G.N., Hunter J.C. Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine. Br. J. Pharmacol. 118:1996;1317-1325.
47. Soar J., Hewson G., Leighton G.E., Hill R.G., Hughes J. L364,718 antagonizes the cholecystokinin-induced suppression of locomotor activity. Pharmacol. Biochem. Behav. 33:1989;637-640.
48. Squire L.R., Davis H.P. The pharmacology of memory: a neurobiological perspective. Ann. Rev. Pharmacol. Toxicol. 21:1981;323-356.
49. B receptor agonist. Psychopharmacology (in press).
50. Thinus-Blanc C. Exploration and spatial knowledge. Thinus-Blanc C. Animal Spatial Cognition: Behavioral and Neural Approaches. 1996;23-42 World Scientific Publishing, Singapore.
51. Vinayek R., Patto R.J., Menozzi D., Gregory J., Mrosinski J.E., Jensen R.T., Gardner J.D. Occupation of low-affinity cholecystokinin (CCK) receptors by CCK activates signal transduction and stimulates amylase secretion pancreatic acinar cells. Biochim. Biophys. Acta. 1176:1993;183-191.